.png)
.png)
Membership directory
We represent over 300 companies. Our members include start-up, emerging and more established bioscience companies, pharmaceutical companies, academic, research and philanthropic organisations, and service providers to the biosciences sector.
Find our members using company name keywords or locations (click on the tabs above and use the search boxes), or use the filters on the right to narrow down your results.
Several of our member companies have sites in multiple locations and so are listed multiple times in the directory. Use the locations tab to view the different sites on the map.
Influence, connect and save with the BIA. Find out about how we can work together.
AbbVie combines the focus and passion of a leading-edge biotech with the expertise and capabilities of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies.
Acacia Pharma develops and commercialises supportive care products for post-surgical and cancer patients. The company addresses these opportunities through repurposing.
Accera is a private Phase 3 development company pioneering novel therapeutics to address metabolic deficiencies in CNS disorders.
ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs.
The Advanced Centre for Biochemical Engineeering hosts the MBI® Modular Training Programme for the Bioindustries.
Hexagon Tower is located in North Manchester and is the UK's only vertical science park and provides a mix of office and laboratory space.
Akcea's mission is to transform treatment for patients with un-addressed or under-addressed rare diseases through leading edge RNA-targeted therapies.